Panel Disdussion

3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of
Nuclear Congress Medicine of Nuclear Medicine
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011
TREATMENT OF DIFFERENTIATED THYROID CARCINOMA,
CONTROVERSIES AND CHALLENGES
M. Eftekhri 1 , S. Farzanefar 2 , B. Fallahi 1 , A. Fard Esfahani 1 , D. Beiki 1 , J.
Esmaili 2 , A. Emami Ardekani 1 , S. Izadyar 2 M. Saghari 1
1 Research Institute for Nuclear Medicine, Tehran University Of Medical Sciences
2 Vali Asr Hospital, Tehran University Of Medical Sciences
Thyroid cancer is a common endocrine malignancy. Despite long term
experience concerning diagnosis and treatment of differentiated
thyroid carcinoma especially more than 70 years experience with I-
131 therapy, still controversies exist regarding appropriate diagnosis,
treatment methods and follow up. Growing advances in technology
including molecular imaging and introduction of new methods for
tumor detection and dosimetry help the caring physicians for optimal
individualized therapy. Type of surgical approach, staging methods,
benefits of I-131 ablation depending on tumor size, ablation dosage,
optimal method for replacement therapy and follow up by serological
and/or different imaging modalities still remain controversial. Other
issues such as low ablative dose of I-131, follow up according to
thyroglobulin level, and radioiodine whole body scan, long term side
effects and possibility of second malignancies need well controlled
studies and clarification. In this presentation these issues and our
own experience at research institute for nuclear medicine Tehran
University of Medical Sciences specially concerns regarding response
versus adverse effects of I-131 are discussed.
Keywords: DTC, Treatment, Radoiodine, Thyroglobulin
64